你可能會喜歡
We’re teaming up with @SarahCannonDocs to bring cancer clinical trials closer to home. Our expanded collaboration accelerates enrollment & expands access—especially for underserved communities. #CancerResearch #Oncology #HealthEquity bit.ly/49gsAri
With @JNJInnovMed, we’re advancing thrombotic research through our Phase 3 Librexia program, the most comprehensive anti-FXIa clinical development program. We’re committed to addressing unmet needs to advance patient care: bit.ly/4hNGnb1 #OneBMS #AHA25
Neuroimaging tools like MRI and PET are changing how we see the brain and helping us advance new options for complex diseases like multiple sclerosis, Alzheimer’s disease and schizophrenia. Learn more: bit.ly/4nIMnDc #OneBMS
We’re looking forward to the 2025 NEI Fall Congress, where we’ll share emerging insights around advancing the science for complex neurological conditions, like schizophrenia and Alzheimer’s. Explore our work in neuroscience: bit.ly/4oQpeQe #OneBMS
At #ACR25, we’re highlighting the unmet needs across rheumatic diseases and how our deeper understanding of these diseases can be leveraged, with the goal of improving patient outcomes. Details below. #OneBMS
Learn how a sequential immunotherapy research framework enables us to address the root cause of disease for those living with immune-mediated diseases in need of meaningful solutions: bit.ly/47oHHMQ #ACR25 #OneBMS
At #ACR25, we’re exploring the potential of CAR T cell therapy in rheumatology, including how rheumatologists can guide patients through clinical trial treatment. Details below. #OneBMS
When cells lose their balance of proteins, too much or too little, it can lead to diseases like cancer and neurodegeneration. Understanding this process is opening new possibilities in treatment. Learn how protein homeostasis is driving innovation: bit.ly/49gekP8 #OneBMS
New episode! Dr. Tania Small & Dr. Heinz-Josef Lenz dive into the future of colorectal cancer care—breakthroughs in detection, treatment, and how lifestyle choices, access and patient-driven data impact survival. A must-watch for oncology changemakers! bit.ly/4nesR0Y
Tomorrow, Dr. @HTawbi_MD will present results from a pooled analysis of combination therapy in patients with advanced melanoma. Visit the poster session in Hall 25 at 12:00-12:45 CEST on Mon., Oct. 20. bit.ly/4nP4Xub
Antibody-drug conjugates (ADCs) are part of the next wave of innovative cancer research, combining monoclonal antibodies with potent therapeutics to target and kill cancer cells while minimizing damage to healthy tissue. bit.ly/4opFVBQ
Tomorrow at #ESMO25, join us in the poster session where Prof. @BenjaminBesseMD will present updated results in adult and pediatric patients with 𝘕𝘛𝘙𝘒+ advanced solid tumors from the TRIDENT-1 and CARE trials Join the session at 12PM CEST in Hall 25, Level 2
Tomorrow, Dr. @PAscierto will present the final, 9-year results from CheckMate 238, a double-blind, phase 3 study of adjuvant treatment trial in resected stage IIIB–C or stage IV #melanoma. Join the session in Hall 7.1a at 14:45 CEST on Sat., Oct. 18 bit.ly/48wliPR
At #ESMO25, our research reflects a commitment to advancing cancer care across diverse modalities. From targeted therapies, bispecific antibodies and ADCs, our core focus is to improve outcomes for patients.
At #ESMO25, we’ll share the latest insights on advancing care for patients with lung cancer. Join us as we explore established therapies and emerging modalities. Learn more below. bit.ly/42Jdsi1 #OneBMS
Tomorrow at #ESMO25, Dr @HelenaYu923 will present the first results from the Ph 1 global study BL-B01D1-LUNG-101, featuring an EGFR × HER3 bispecific ADC in metastatic or unresectable NSCLC & other solid tumors. Join the session at 4PM CEST in the Heidelberg Auditorium, Hall 6.2
Join us at #ESMO25 as we explore evolving approaches, real-world insights and emerging therapies shaping the future of gastrointestinal cancer care. Details below. bit.ly/47pHaLu #OneBMS
Cells recycle proteins using a natural tagging system. Advancing targeted protein degradation allows us to pursue new treatment options. Explore how this science is helping drive innovation for patients: bit.ly/470XB0Z #OneBMS
Join us at #APNA2025 for a focused look into schizophrenia. Hara Oyedeji, PMHNP-BC, will explore the clinical biological complexity of schizophrenia.
Discover new insights in neuropsychiatric care at #ECNP2025. Prakash Masand, MD and Professor Charlotte Teunissen, PhD will review cholinergic mechanisms and unmet needs in schizophrenia and Alzheimer’s disease.
United States 趨勢
- 1. Jokic 19.7K posts
- 2. Lakers 53.5K posts
- 3. #AEWDynamite 47.5K posts
- 4. Epstein 1.56M posts
- 5. Nemec 2,471 posts
- 6. Clippers 12.1K posts
- 7. Shai 15.9K posts
- 8. #NJDevils 2,848 posts
- 9. Thunder 42.6K posts
- 10. #Blackhawks 1,584 posts
- 11. Markstrom 1,005 posts
- 12. #AEWBloodAndGuts 5,728 posts
- 13. Nemo 8,498 posts
- 14. Sam Lafferty N/A
- 15. Darby 5,581 posts
- 16. #Survivor49 3,808 posts
- 17. Steph 27.8K posts
- 18. Kyle O'Reilly 2,076 posts
- 19. Rory 7,605 posts
- 20. Spencer Knight N/A
你可能會喜歡
-
Sean Davis
@seanmdav -
Allogene Therapeutics
@AllogeneTx -
Amgen Oncology
@AmgenOncology -
Lilly Medical US
@LillyMedical -
Novartis US
@NovartisUS -
Carl T 💪🏾💯👊🏽🕶🐶
@CTyroneD -
Novartis US Medical
@NovartisUSMed -
JCharlesAssets 🌊
@JCharlesAssets -
Pfizer Oncology Medical
@PfizerOncMed -
NetSmartz
@NetSmartz -
VacationRenter
@VacationRenter_ -
Stefano Crippa
@StefanoCrippa6 -
UCB US
@UCBUSA -
McCormick Corporate
@McCormickCorp -
James H. Flint, MD, FACS, FAAOS
@DryBones373
Something went wrong.
Something went wrong.